Ballard C, Aarsland D, Cummings J, O’Brien J, Mills R, Molinuevo JL, et al. Drug repositioning and repurposing for Alzheimer disease. Nat Rev Neurol. 2020;16(12):661–73.

Article  PubMed  PubMed Central  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023.

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.

Article  CAS  PubMed  Google Scholar 

Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 2016;24(1):15–30.

Article  CAS  PubMed  Google Scholar 

Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen T, Wen S, Gong M, Yuan X, Xu D, Wang C, et al. Dapagliflozin activates neurons in the Central Nervous System and regulates Cardiovascular activity by inhibiting SGLT-2 in mice. Diabetes Metab Syndr Obes. 2020;13:2781–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 2007;203(2):293–301.

Article  CAS  PubMed  Google Scholar 

During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9(9):1173–9.

Article  CAS  PubMed  Google Scholar 

Abbas T, Faivre E, Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer’s disease. Behav Brain Res. 2009;205(1):265–71.

Article  CAS  PubMed  Google Scholar 

Norgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, Moller DV, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement (N Y). 2022;8(1):e12268.

Article  PubMed  Google Scholar 

Wium-Andersen IK, Osler M, Jorgensen MB, Rungby J, Wium-Andersen MK. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study. Eur J Endocrinol. 2019;181(5):499–507.

Article  CAS  PubMed  Google Scholar 

De Giorgi R, Koychev I, Adler A, Cowen P, Harmer JC, Harrison P et al. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. EClinicalMedicine. 2024.

Timsina J, Gomez-Fonseca D, Wang L, Do A, Western D, Alvarez I, et al. Comparative analysis of Alzheimer’s Disease Cerebrospinal fluid biomarkers measurement by Multiplex SOMAscan platform and immunoassay-based Approach. J Alzheimers Dis. 2022;89(1):193–207.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S, et al. Alzheimer’s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement. 2014;10(6):724–34.

Article  PubMed  Google Scholar 

Shi L, Winchester LM, Westwood S, Baird AL, Anand SN, Buckley NJ, et al. Replication study of plasma proteins relating to Alzheimer’s pathology. Alzheimers Dement. 2021;17(9):1452–64.

Article  CAS  PubMed  Google Scholar 

Iwamoto N, Nishiyama E, Ohwada J, Arai H. Demonstration of CRP immunoreactivity in brains of Alzheimer’s disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett. 1994;177(1):23–6.

Article  CAS  PubMed  Google Scholar 

Smits LL, Pijnenburg YA, van der Vlies AE, Koedam EL, Bouwman FH, Reuling IE, et al. Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains. Eur Neuropsychopharmacol. 2015;25(7):1010–7.

Article  CAS  PubMed  Google Scholar 

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly Exenatide on Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coccaro EF, Lee R, Coussons-Read M. Cerebrospinal fluid and plasma C-reactive protein and aggression in personality-disordered subjects: a pilot study. J Neural Transm (Vienna). 2015;122(2):321–6.

Article  CAS  PubMed  Google Scholar 

Yasojima K, Schwab C, McGeer EG, McGeer PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res. 2000;887(1):80–9.

Article  CAS  PubMed  Google Scholar 

Guo H, Wang H, Wang C, Cheng Y, Zou Z, Li Y, et al. C-Reactive protein induces tau hyperphosphorylation via GSK3β Signaling Pathway in SH-SY5Y cells. J Mol Neurosci. 2015;56(2):519–27.

Article  CAS  PubMed  Google Scholar 

Long S, Chen Y, Meng Y, Yang Z, Wei M, Li T, et al. Peripheral high levels of CRP predict progression from normal cognition to dementia: a systematic review and meta-analysis. J Clin Neurosci. 2023;107:54–63.

Article  CAS  PubMed  Google Scholar 

Tao Q, Alvin Ang TF, Akhter-Khan SC, Itchapurapu IS, Killiany R, Zhang X, et al. Impact of C-Reactive protein on Cognition and Alzheimer Disease biomarkers in homozygous apolipoprotein E ɛ4 carriers. Neurology. 2021;97(12):e1243–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Caterina R, Basta G, Lazzerini G, Dell’Omo G, Petrucci R, Morale M, et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17(11):2646–54.

Article  PubMed  Google Scholar 

Tchalla AE, Wellenius GA, Travison TG, Gagnon M, Iloputaife I, Dantoine T, et al. Circulating vascular cell adhesion molecule-1 is associated with cerebral blood flow dysregulation, mobility impairment, and falls in older adults. Hypertension. 2015;66(2):340–6.

Article  CAS  PubMed  Google Scholar 

Wang C, Reid G, Mackay CE, Hayes G, Bulte DP, Suri S. A systematic review of the association between dementia risk factors and cerebrovascular reactivity. Neurosci Biobehavioral Reviews. 2023;148:105140.

Article  CAS  Google Scholar 

Zuliani G, Cavalieri M, Galvani M, Passaro A, Munari MR, Bosi C, et al. Markers of endothelial dysfunction in older subjects with late onset Alzheimer’s disease or vascular dementia. J Neurol Sci. 2008;272(1–2):164–70.

Article  CAS  PubMed  Google Scholar 

Schubert CR, Fischer ME, Pinto AA, Paulsen AJ, Chen Y, Huang G-H, et al. Inflammation, metabolic dysregulation and environmental neurotoxins and risk of cognitive decline and impairment in midlife. Neurol Sci. 2023;44(1):149–57.

Article  PubMed  Google Scholar 

Matsushita M, Fujita T. The role of Ficolins in Innate Immunity. Immunobiology. 2002;205(4):490–7.

Article  CAS  PubMed  Google Scholar 

Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN et al. Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-Flutemetamol PET scan result. Front Aging Neurosci. 2018;10.

Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metabolism. 2012;97(1):198–207.

Article  CAS  Google Scholar 

Bułdak Ł, Machnik G, Bułdak RJ, Łabuzek K, Bołdys A, Belowski D, et al. Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner. Pharmacol Rep. 2016;68(2):329–37.

Article  PubMed  Google Scholar 

Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin. 2012;33(1):75–81.

Article